V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 330011975 | 330005951 | 0 | 65.8 | Palliative (P) | 2014-11-15 | 2014-11-15 | PONATINIB | N | null | 330024869 | IRINOTECAN + MDG |
| 330011977 | 330005954 | 1.75 | 19 | Palliative (P) | 2014-01-04 | 2014-01-04 | BORTEZOMIB + RITUXIMAB | N | N | 330024882 | DOXORUBICIN + HD MTX |
| 330011978 | 330005956 | 1.78 | 62 | Neo-adjuvant (N) | 2016-01-14 | 2016-01-15 | DHAP | N | N | 330024888 | PILOT TRIAL |
| 330011980 | 330005964 | 1.86 | 68 | Disease modification (D) | 2016-07-26 | 2016-07-26 | CISPLATIN + ETOPOSIDE + IFOSFAMIDE | 02 | N | 330024984 | VIDE |
| 330011981 | 330005966 | 1.63 | null | Palliative (P) | 2017-07-10 | 2017-07-17 | BCG Intravesical | 02 | N | 330024986 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN |
| 330011982 | 330005971 | 1.82 | 69 | Adjuvant (A) | 2018-08-06 | 2018-09-26 | CLADRIBINE | N | null | 330025024 | IRINOTECAN + MDG |
| 330011983 | 330005975 | 1.68 | 88.5 | null | null | 2015-08-22 | CISPLATIN + DACTINOMYCIN + ETOPOSIDE + METHOTREXATE | 02 | N | 330025032 | FLUDARABINE + MELPHALAN |
| 330011984 | 330005977 | 1.67 | 9.5 | Disease modification (D) | 2014-10-16 | 2014-10-26 | CLADRIBINE | 2 | N | 330025041 | PEMBROLIZUMAB |
| 330011985 | 330009256 | 1.74 | null | Curative (C) | 2015-07-09 | 2015-07-14 | AML 19 TRIAL | N | N | 330025041 | VIDE |
| 330011986 | 330009257 | 1.64 | null | Curative (C) | 2019-02-06 | 2019-04-27 | EMA/CO | 02 | N | 330025052 | EP/EMA |
| 330011987 | 330013098 | 1.7 | 92.1 | Palliative (P) | 2016-09-09 | 2016-09-09 | AML17 TRIAL | 2 | N | 330000188 | AML17 TRIAL |
| 330011988 | 330005984 | 1.62 | 72.4 | null | 2017-04-22 | 2017-04-22 | CLADRIBINE | N | N | 330000343 | GEMCITABINE |
| 330011989 | 330005986 | 1.8 | 62 | Palliative (P) | 2017-07-06 | 2017-07-06 | CARBOPLATIN + Cetuximab + FLUOROURACIL | 2 | N | 330000507 | AML18 TRIAL |
| 330011990 | 330005989 | null | 20.1 | Curative (C) | 2017-06-01 | 2017-06-17 | Topotecan (intravenous) | 02 | N | 330000556 | CYCLOPHOSPHAMIDE HIGH DOSE |
| 330011991 | 330009267 | 1.68 | 66.2 | Curative (C) | 2015-05-02 | 2015-08-11 | Dox + HD Mtx (post PAM) | N | N | 330000770 | FLUOROURACIL + MITOMYCIN + RT |
| 330011992 | 330006002 | 1.67 | 35.8 | Neo-adjuvant (N) | 2016-10-23 | 2016-10-24 | BORTEZOMIB + RITUXIMAB | N | null | 330004380 | IDARUBICIN |
| 330011993 | 330006006 | null | 70 | Palliative (P) | 2014-08-28 | 2014-10-13 | ALL UKALL2011 Consolidation A | N | N | 330004663 | MVAC |
| 330011994 | 330011045 | null | 110.5 | Palliative (P) | 2014-10-22 | 2014-11-27 | CYCLOPHOSPHAMIDE | Y | N | 330004773 | TRIPLE INTRATHECAL |
| 330011995 | 330006012 | 1.76 | 76 | Curative (C) | 2017-07-29 | 2017-08-08 | CHLORAMBUCIL + RITUXIMAB | N | N | 330004965 | CYCLOPHOSPHAMIDE HIGH DOSE |
| 330011996 | 330006014 | null | null | Palliative (P) | null | 2016-06-26 | Capecitabine | null | null | 330004965 | CARBOPLATIN + PEMETREXED |
| 330011997 | 330006016 | null | 63 | Palliative (P) | 2018-07-30 | 2018-08-12 | Cyclophosphamide High Dose | N | N | 330005236 | CVD |
| 330011998 | 330006017 | null | 74.4 | Not known (9) | 2019-03-15 | 2019-05-18 | Hydroxycarbamide | N | N | 330005446 | CYTARABINE INTRATHECAL |
| 330011999 | 330009279 | 1.69 | 16.1 | Curative (C) | 2018-08-17 | 2018-08-21 | GEMCITABINE | 2 | N | 330006301 | CHOP R |
| 330012000 | 330009280 | null | 18 | Curative (C) | 2015-11-14 | 2015-12-21 | AML Int Guide ADE 10+3+5 (1) | Y | N | 330006361 | CASPS TRIAL |
| 330012001 | 330006025 | 1.71 | 109 | Disease modification (D) | 2018-05-19 | 2018-05-19 | CARBOPLATIN + CETUXIMAB + FU | null | null | 330006669 | PAC-E |
| 330012002 | 330009284 | 1.77 | null | Disease modification (D) | 2019-01-08 | 2019-01-21 | FCR Oral - Cycle 2 onwards | N | N | 330006782 | FLUDARABINE |
| 330012003 | 330006029 | 1.8 | 76.4 | Curative (C) | 2018-03-30 | 2018-12-12 | Cyclophosphamide High Dose | 2 | N | 330006932 | CAP |
| 330012004 | 330011057 | 1.79 | 79 | null | 2016-09-15 | 2016-12-30 | BORTEZOMIB + RITUXIMAB | N | null | 330007236 | CYCLOPHOSPHAMIDE + VINCRISTINE |
| 330012005 | 330006032 | 1.65 | 8.9 | Curative (C) | 2017-03-06 | 2018-07-03 | Hydroxycarbamide | 02 | N | 330007632 | DACARBAZINE |
| 330012006 | 330006040 | 1.67 | 71.1 | Palliative (P) | 2017-08-13 | 2017-08-13 | Pazopanib | 02 | N | 330008201 | IFOSFAMIDE |
| 330012007 | 330006041 | 0 | 86.6 | Curative (C) | 2019-03-11 | 2019-03-25 | BCG Intravesical | Y | N | 330008362 | DASATINIB |
| 330012008 | 330009290 | 1.73 | null | Disease modification (D) | 2015-04-15 | 2015-04-15 | IPO | N | N | 330008837 | GEMCITABINE + OXALIPLATIN |
| 330012009 | 330006046 | null | 62.5 | Curative (C) | 2018-09-02 | 2018-09-02 | CISPLATIN + DACTINOMYCIN + ETOPOSIDE + METHOTREXATE | 02 | N | 330009579 | BORTEZOMIB |
| 330012010 | 330009294 | 1.91 | 77 | Palliative (P) | 2018-06-22 | 2018-06-22 | CYCLOPHOSPHAMIDE | 02 | N | 330009845 | IMATINIB |
| 330012011 | 330006052 | 1.76 | 12.4 | null | 2018-04-17 | 2018-04-20 | Carboplatin + Cetux + FU (Cycle 1) | N | N | 330009954 | DACTINOMYCIN + VINCRISTINE |
| 330012012 | 330006055 | 1.8 | null | Curative (C) | 2018-05-08 | 2018-05-09 | IMATINIB | 02 | N | 330010132 | CYTARABINE |
| 330012013 | 330006057 | null | 50 | Neo-adjuvant (N) | 2015-11-09 | 2016-02-23 | Bortezomib +/- Dexamethasone | null | null | 330010223 | CYCLOPHOSPHAMIDE HIGH DOSE |
| 330012014 | 330006059 | 1.76 | 117.8 | Adjuvant (A) | 2017-03-18 | 2017-03-18 | UKALL14- Ph 2 Induction | N | null | 330010514 | CAP |
| 330012015 | 330006063 | 1.61 | 64 | Palliative (P) | 2015-03-08 | 2015-03-09 | CYTARABINE | N | N | 330010809 | DASATINIB |
| 330012016 | 330006068 | 1.7 | 109 | Palliative (P) | 2018-09-28 | 2018-09-28 | Doxorubicin + Olaratumab | 2 | N | 330011080 | EMA/CO |
| 330012017 | 330006072 | 1.71 | 61.5 | Palliative (P) | 2017-09-17 | 2017-09-17 | Dox + HD Mtx (post PAM) | 01 | N | 330011853 | LOMUSTINE + PROCARBAZINE |
| 330012018 | 330006078 | 1.38 | 65.8 | null | 2016-12-27 | 2017-01-11 | Cisplatin + Fluorouracil + RT 5day | N | N | 330012226 | CHLORAMBUCIL |
| 330012019 | 330006079 | 1.68 | 12.7 | Curative (C) | 2015-10-26 | 2015-10-26 | STS Rhabdomyosarcoma RMS 2005 VA | 02 | N | 330012831 | CYCLO + DOXORUBICIN + VINCRISTINE |
| 330012020 | 330006082 | null | 74.4 | Palliative (P) | 2016-03-17 | 2016-07-28 | Ifosfamide | N | N | 330015108 | LIPOSOMAL DAUNORUBICIN |
| 330012021 | 330006085 | 1.73 | 62 | Curative (C) | null | 2019-07-27 | Mitotane 3 - 3.5g | N | N | 330015148 | ADE |
| 330012022 | 330011072 | null | 10.8 | Curative (C) | 2016-02-04 | 2016-02-06 | BLEOMYCIN + VINCRISTINE | N | null | 330015218 | CAPECITABINE + CISPLATIN |
| 330012023 | 330006089 | 1.55 | 57.5 | Disease modification (D) | 2017-06-23 | 2017-06-23 | Chlorambucil | N | N | 330015310 | CETUXIMAB + CISPLATIN + FU |
| 330012024 | 330006091 | 1.75 | 120.1 | Palliative (P) | 2015-03-03 | 2015-03-07 | Ifosfamide | 02 | N | 330015434 | IDARUBICIN |
| 330012025 | 330009318 | null | 50.2 | Disease modification (D) | 2017-09-02 | 2017-10-14 | Dox + HD Mtx (post PAM) | N | N | 330015442 | MERCAPTOPURINE + METHOTREXATE |
| 330012026 | 330009319 | 1.58 | 58.9 | Palliative (P) | 2015-02-11 | 2015-02-11 | VINCRISTINE | N | N | 330015685 | CHLORAMBUCIL + RITUXIMAB |